The HealthShares Emerging Cancer(HHJ Quote) exchange-traded fund was Friday's best performer. Dendreon(DNDN Quote) soared 164.2% after the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. The ETF was jumping $2.40, or 10.7%, to $24.82.
Other biotech and health care ETFs were gaining ground. The PowerShares FTSE RAFI Health Care(PRFH Quote) was adding 4% to $50.98. The First Trust Amex Biotechnology Index(FBT Quote) was gaining 1% to $23.84. The SPDR S&P Biotech(XBI Quote) was up 0.9% at $48.22.
On the other hand, the B2B Internet HOLDRs(BHH Quote) ETF was lower, as holdings Ariba(ARBA Quote) and Checkfree(CKFR Quote) were shedding 1.5%. The ETF was off 4 cents, or 1.8%, to $2.14. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,281.05 | 1,088.31 | 2,124.70 | 32.25 |
Oil *
77.38
|
|
DOWN
28.87
|
DOWN
3.18
|
DOWN
13.74
|
DOWN
0.06
|
10 Yr
3.22%
SPDR Gold
114.89
|
|
-0.28%
|
-0.29%
|
-0.64%
|
-0.19%
|
Data delayed 20 minutes |
Connect with TheStreet